

# Dan G Sunnemark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5307635/publications.pdf>

Version: 2024-02-01

20  
papers

1,207  
citations

430874

18  
h-index

713466

21  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2371  
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2021, 114, 103641.	2.2	15
2	Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein. <i>Brain Research</i> , 2020, 1749, 147131.	2.2	21
3	Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease. <i>Cell and Tissue Research</i> , 2017, 369, 445-454.	2.9	79
4	Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5409-5414.	7.1	79
5	MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies. <i>Acta Neuropathologica Communications</i> , 2014, 2, 22.	5.2	73
6	Role of Individual MARK Isoforms in Phosphorylation of Tau at Ser262 in Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 458-469.	3.4	54
7	Elevated MARK2-Dependent Phosphorylation of Tau in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 699-713.	2.6	48
8	Tau-Tubulin Kinase 1 Expression, Phosphorylation and Co-Localization with Phospho-Ser422 Tau in the Alzheimer's Disease Brain. <i>Brain Pathology</i> , 2013, 23, 378-389.	4.1	40
9	Characterization of AZD4694, a novel fluorinated A $\beta$ 2 plaque neuroimaging PET radioligand. <i>Journal of Neurochemistry</i> , 2010, 114, 784-794.	3.9	121
10	Pivotal Advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1248-1255.	3.3	183
11	Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. <i>Neurobiology of Aging</i> , 2008, 29, 1423-1433.	3.1	97
12	Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. <i>Journal of Neuroinflammation</i> , 2007, 4, 14.	7.2	70
13	CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. <i>Journal of Neuroinflammation</i> , 2005, 2, 17.	7.2	113
14	Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease. <i>Journal of Neuroimmunology</i> , 2003, 142, 75-85.	2.3	36
15	CBA/J mice infected with <i>Trypanosoma cruzi</i> : An experimental model for inflammatory myopathies. <i>Muscle and Nerve</i> , 2003, 27, 442-448.	2.2	19
16	Chronic murine Chagas' disease: the impact of host and parasite genotypes. <i>Immunology Letters</i> , 2003, 86, 207-212.	2.5	29
17	Dihydropyrimidinase related protein-2 as a biomarker for temperature and time dependent post mortem changes in the mouse brain proteome. <i>Proteomics</i> , 2003, 3, 1920-1929.	2.2	56
18	Differential Expression of the Chemokine Receptors CX <sub>3</sub> CR1 and CCR1 by Microglia and Macrophages in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis. <i>Brain Pathology</i> , 2003, 13, 617-629.	4.1	37

#	ARTICLE	IF	CITATIONS
19	Induction of early atherosclerosis in CBA/J mice by combination of Trypanosoma cruzi infection and a high cholesterol diet. <i>Atherosclerosis</i> , 2000, 153, 273-282.	0.8	25
20	Enhanced prevalence of T cells expressing TCRBV8S2 and TCRBV8S3 in hearts of chronically Trypanosoma cruzi-infected mice. <i>Immunology Letters</i> , 1998, 60, 171-177.	2.5	10